Dexrazoxane (Zinecard)

From - A Hematology Oncology Wiki
(Redirected from Dexrazoxane (Totect))
Jump to navigation Jump to search

General information

Class/mechanism: Intracellular chelating agent derived from EDTA. Mechanism not fully understood, but hypothesized to protect against anthracycline-caused cardiomyopathy by interfering with iron-mediated free radical generation. Also used in cases of anthracycline extravasation.[1][2][3][4][5]
Route: IV
Extravasation: no information

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Efficacy references

  1. Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, Knoblauch P, Rasmussen A, Dahlstrøm K, Jensen PB, Giaccone G. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol. 2007 Mar;18(3):546-50. Epub 2006 Dec 21. PubMed
  2. POG 9404: Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, Camitta BM, Lipshultz SE. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: A report of the Children's Oncology Group randomized trial Pediatric Oncology Group 9404. J Clin Oncol. 2016 Mar 10;34(8):854-62. Epub 2015 Dec 23. link to original article link to PMC article PubMed

Patient drug information

Also known as

  • Code names: ADR-529, ICRF-187
  • Generic name: dexrazoxane hydrochloride
  • Brand names: Cardioxane, Cyrdanax, Savene, Totect, Zinecard